Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus NEOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus NEOBIOTIC.
CHLOROMYXIN vs NEOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
1 g intravenously every 12 hours.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Antibiotic
Antibiotic